To specifically test the significance of TP53 and KRAS concurrent mutations, we performed an analysis using a pan-cancer cohort of 9125 TCGA patients and found only 2.1% (191 out of 9125) harbor mutations in both TP53 and KRAS simultaneously, suggesting that double mutated TP53 and KRAS genes tend to be enriched in the YST patients with gonadal dysgenesis (Fisher’s exact test, p = 5.3 × 10−4). The gene discussed is KRAS; the disease is cancer.